Electrostatic analysis of TEM1 β-lactamase: effect of substrate binding, steep potential gradients and consequences of site-directed mutations

Swarén, Peter; Maveyraud, Laurent; Guillet, Valérie; Masson, Jean-Michel; Mourey, Lionel; Samama, Jean‐Pierre

doi:10.1016/s0969-2126(01)00194-0

Cited by 57 publications

(74 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, TEM variant enzymes with an N276D substitution are inhibitor resistant. It is thought that the negative charge of the aspartate neutralizes the positive charge of the R244 guanidinium group (55). In BlaC, E276 is in close proximity to R220 (2.6 Å), already weakening the positive charge of guanidinium.…”

Section: Discussionmentioning

confidence: 99%

Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations

Kurz

Wolff

Hazra

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The current emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis calls for novel treatment strategies. Recently, BlaC, the principal ␤-lactamase of Mycobacterium tuberculosis, was recognized as a potential therapeutic target. The combination of meropenem and clavulanic acid, which inhibits BlaC, was found to be effective against even extensively drug-resistant M. tuberculosis strains when tested in vitro. Yet there is significant concern that drug resistance against this combination will also emerge. To investigate the potential of BlaC to evolve variants resistant to clavulanic acid, we introduced substitutions at important amino acid residues of M. tuberculosis BlaC (R220, A244, S130, and T237). Whereas the substitutions clearly led to in vitro clavulanic acid resistance in enzymatic assays but at the expense of catalytic activity, transformation of variant BlaCs into an M. tuberculosis H37Rv background revealed that impaired inhibition of BlaC did not affect inhibition of growth in the presence of ampicillin and clavulanate. From these data we propose that resistance to ␤-lactam-␤-lactamase inhibitor combinations will likely not arise from structural alteration of BlaC, therefore establishing confidence that this therapeutic modality can be part of a successful treatment regimen against M. tuberculosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations

Kurz

Wolff

Hazra

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…A second view of acylation maintains that Lys73 can serve as the general base deprotonating Ser70 (166,261,401). Recent QM/MM studies by Meroueh et al demonstrate that the pathway involving Lys73 as the activating base is energetically favorable and may exist in competition with the pathway where Glu166 serves as the activating residue (261).…”

Section: ␤-Lactamase Hydrolytic Mechanismsmentioning

confidence: 99%

Three Decades of β-Lactamase Inhibitors

Drawz¹,

2010

View full text Add to dashboard Cite

SUMMARYSince the introduction of penicillin, β-lactam antibiotics have been the antimicrobial agents of choice. Unfortunately, the efficacy of these life-saving antibiotics is significantly threatened by bacterial β-lactamases. β-Lactamases are now responsible for resistance to penicillins, extended-spectrum cephalosporins, monobactams, and carbapenems. In order to overcome β-lactamase-mediated resistance, β-lactamase inhibitors (clavulanate, sulbactam, and tazobactam) were introduced into clinical practice. These inhibitors greatly enhance the efficacy of their partner β-lactams (amoxicillin, ampicillin, piperacillin, and ticarcillin) in the treatment of seriousEnterobacteriaceaeand penicillin-resistant staphylococcal infections. However, selective pressure from excess antibiotic use accelerated the emergence of resistance to β-lactam-β-lactamase inhibitor combinations. Furthermore, the prevalence of clinically relevant β-lactamases from other classes that are resistant to inhibition is rapidly increasing. There is an urgent need for effective inhibitors that can restore the activity of β-lactams. Here, we review the catalytic mechanisms of each β-lactamase class. We then discuss approaches for circumventing β-lactamase-mediated resistance, including properties and characteristics of mechanism-based inactivators. We next highlight the mechanisms of action and salient clinical and microbiological features of β-lactamase inhibitors. We also emphasize their therapeutic applications. We close by focusing on novel compounds and the chemical features of these agents that may contribute to a “second generation” of inhibitors. The goal for the next 3 decades will be to design inhibitors that will be effective for more than a single class of β-lactamases.

show abstract

“…Lys 73 (42)(43)(44) and/or Glu 166 (45)(46)(47) in class A ␤-lactamases, Tyr 150 in class C ␤-lactamases (48), carboxylated Lys 70 in class D ␤-lactamases (49), and unprotonated Lys 392 in PBPs (50, 51)) (Fig. 6).…”

Section: Role Of Lys 392 As the General Base In Acylation-mentioning

confidence: 99%

Crystal Structures of the Apo and Penicillin-acylated Forms of the BlaR1 β-Lactam Sensor of Staphylococcus aureus

Wilke

Hills

Zhang

et al. 2004

Journal of Biological Chemistry

View full text Add to dashboard Cite

Staphylococcus aureus is among the most prevalent and antibiotic-resistant of pathogenic bacteria. The resistance of S. aureus to prototypal ␤-lactam antibiotics is conferred by two mechanisms: (i) secretion of hydrolytic ␤-lactamase enzymes and (ii) production of ␤-lactam-insensitive penicillin-binding proteins (PBP2a). Despite their distinct modes of resistance, expression of these proteins is controlled by similar regulation systems, including a repressor (BlaI/MecI) and a multidomain transmembrane receptor (BlaR1/MecR1). Resistance is triggered in response to a covalent binding event between a ␤-lactam antibiotic and the extracellular sensor domain of BlaR1/MecR1 by transduction of the binding signal to an intracellular protease domain capable of repressor inactivation. This study describes the first crystal structures of the sensor domain of BlaR1 (BlaR S ) from S. aureus in both the apo and penicillin-acylated forms. The structures show that the sensor domain resembles the ␤-lactam-hydrolyzing class D ␤-lactamases, but is rendered a penicillin-binding protein due to the formation of a very stable acyl-enzyme. Surprisingly, conformational changes upon penicillin binding were not observed in our structures, supporting the hypothesis that transduction of the antibiotic-binding signal into the cytosol is mediated by additional intramolecular interactions of the sensor domain with an adjacent extracellular loop in BlaR1.The evolution and dissemination of antibiotic resistance in pathogenic bacteria are a growing concern. Many of the antimicrobial "wonder drugs" society has come to rely on for the treatment of bacterial infections have been neutralized by new strains equipped with a variety of molecular countermeasures. Methicillin-resistant Staphylococcus aureus is a prominent example of this (1-3). Although ␤-lactam antibiotics such as penicillin have long been the drugs of choice for infections of S. aureus, current therapies for methicillin-resistant S. aureus infections now depend on distinct antibiotic classes such as glycopeptides to counter the increased resistance to penicillin and its derivatives. The recent emergence of glycopeptide-resistant strains of S. aureus (4, 5) underscores the need not only for the development of novel therapeutics, but for better understanding of the molecular mechanisms involved in antibiotic resistance.␤-Lactam antibiotics kill bacteria by inhibiting the cell wall transpeptidases (also known as penicillin-binding proteins (PBPs) 1 ) that are responsible for the essential cross-linking of peptidoglycan during synthesis of the rigid bacterial cell wall. Resistance to ␤-lactam antibiotics in S. aureus can be conferred by two mechanisms. In one case, ␤-lactamase enzymes are secreted from the bacterium to hydrolytically inactivate ␤-lactam antibiotics. Resistance of this form is encoded by the blaZ gene and is carried by Ͼ95% of S. aureus isolates (3). The second resistance mechanism is expression of PBP2a, a cell wall transpeptidase with broad-spectrum insensitivity to ␤-lacta...

show abstract

Electrostatic analysis of TEM1 β-lactamase: effect of substrate binding, steep potential gradients and consequences of site-directed mutations

Cited by 57 publications

References 39 publications

Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations

Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations

Three Decades of β-Lactamase Inhibitors

Crystal Structures of the Apo and Penicillin-acylated Forms of the BlaR1 β-Lactam Sensor of Staphylococcus aureus

Contact Info

Product

Resources

About